Lou Jing

Biography

Mr. LOU Jing (婁競) was appointed as a Director of our Company on September 5, 2006 and was redesignated as an executive Director of our Company on November 27, 2014. He was appointed as the chairman of the Board on April 1, 2012. Dr. Lou is also our chief executive officer and president. He is responsible for the strategic development and planning, overall operational management and major decision making of our Group. He joined Shenyang Sunshine as a director of research and development in September 1995. Dr. Lou has been highly active in pharmaceutical research and has made substantial contribution to our research and development of pharmaceutical products. Dr. Lou was the leading scientist and principal investigator in our successful development of EPIAO and TPIAO. He co-invented a “preparation process for recombinant human thrombopoietin” and a “method for improving the stability of polypeptides in human bodies and its application” in 2000 and 2001, respectively. He has published in a number of academic journals on microbiology and medicinal biotechnology. His research has been recognized with various awards. In 2006, he was awarded the “Shenyang Science and Technology Progress Award” (瀋陽市科學技術進步一等獎) for his research on recombinant human thrombopoietin. In 2007, he was awarded the “Liaoning Province Scientific and Technological Achievements Prize” (遼寧省科技成果轉化三等獎) for his contribution to the industrialization of production of recombinant human thrombopoietin. Dr. Lou was also selected as a member of “The Recruitment Program of Global Experts”, which is also known as the “Thousand Talents Program (千人計劃)”, in March 2013. Dr. Lou obtained a Medical Doctor degree (M.D.) in clinical medicine from Shanghai Second Military Medical University (上海第二軍醫大學) in July 1985. He conducted post-doctoral research at the National Institutes of Health of the United States after obtaining a Ph.D. degree in molecular and cell biology from Fordham University in February 1994. He also obtained an Executive Master of Business Administration from China Europe International Business School (中歐國際工商學院) in September 2008.

Research Interest

pharmaceutical research